|Title:||Treatment of partial growth hormone insensitivity syndrome|
|Abstract:||Methods for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, but not Laron syndrome, are described. One such method comprises administering an effective dose of growth hormone, preferably growth hormone with a native human sequence, with or without an N-terminal methionine, to the patient. The patient is characterized as having a height of less than about -2 standard deviations below normal for age and sex, a serum level of high-affinity growth hormone binding protein that is at least 2 standard deviations below normal levels, a serum level of IGF-I that is below normal mean levels, and a serum level of growth hormone that is at least normal. In another such method, the same patient population is treated with an effective amount of IGF-I, given alone or in combination with an amount of growth hormone that is effective in combination with the IGF-I.|
|Inventor(s):||Attie; Kenneth M. (San Francisco, CA), Carlsson; Lena M. S. (Gothenburg, SE), Gesundheit; Neil (Los Altos, CA), Goddard; Audrey (San Francisco, CA)|
|Assignee:||Genentech, Inc. (South San Francisco, CA)|
Patent Claim Types:|
see list of patent claims
Field: Not categorized
Back Citations: 4th percentile
Forward Citations: 0th percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.